Open Beta
TREN
MetriLume
TREN

US marketsABCL

SEC-sourced researchBeta

ABCL

AbCellera Biologics Inc.

Company comparison ↗

Data passport

CIK
0001703057
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Aug 24, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 38,025,000.0000 USD; December 2024: 28,833,000.0000 USD; December 2025: 75,128,000.0000 USD75.1M USD0 USD0December 2023December 2024December 2025
ABCL · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202338,025,000.0000Feb 24, 2026
December 202428,833,000.0000Feb 24, 2026
December 202575,128,000.0000Feb 24, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202575,128,000.0000-146,412,000.0000-131,295,000.00001,356,950,000.0000390,046,000.0000Feb 24, 2026
December 202428,833,000.0000-162,857,000.0000-108,556,000.00001,360,553,000.0000304,469,000.0000Feb 24, 2026
December 202338,025,000.0000-146,398,000.0000-43,877,000.0000——Feb 24, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

54/100
Profitability0
Growth100
Balance sheet71
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$75.13MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$28.83MJan 1, 2024 – Dec 31, 2024Feb 24, 202610-K
Net incomeNetIncomeLoss-$146.41MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$131.3MJan 1, 2025 – Dec 31, 2025Feb 24, 202610-K
Total assetsAssets$1.36BDec 31, 2025Feb 24, 202610-K
Total liabilitiesLiabilities$390.05MDec 31, 2025Feb 24, 202610-K

New filings

Explore methodology ↗